Piramal Pharma jumped 8% after JM Financial raised EPS forecasts and hiked its target price to ₹313, citing a $50-100M annual revenue deal with NewAmsterdam Pharma. SEBI analyst Sameer Pande flagged a technical breakout, setting a target of ₹229 by October with stop loss at ₹180. Stocktwits sentiment turned bullish.